What is the treatment for Hepatitis A (infectious liver disease)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Hepatitis A

Hepatitis A requires only supportive care, as no specific antiviral therapy exists or is necessary for this self-limited infection. 1, 2

Acute Phase Management

The cornerstone of treatment is symptomatic support with strict avoidance of hepatotoxic medications. 2 This includes:

  • Rest, adequate hydration, and symptomatic relief as needed 1
  • High-calorie diet to support recovery 3
  • Strict avoidance of all hepatotoxic medications and drugs metabolized by the liver during acute illness 2
  • Complete abstinence from alcohol 3
  • Avoid excessive acetaminophen (>2 g/day) and hepatotoxic herbal supplements 1

Hospitalization Criteria

Hospitalize patients who develop dehydration from nausea and vomiting or show any signs suggesting acute liver failure. 1, 2 Intravenous rehydration becomes necessary when patients cannot maintain adequate oral intake. 3

Disease Course and Monitoring

The clinical course varies significantly:

  • Most patients recover uneventfully within 2 months 4
  • 10-15% experience prolonged or relapsing disease lasting up to 6 months, with approximately 20% of relapsing cases having multiple recurrences 2
  • Fulminant hepatitis is rare (0.015-0.5% incidence) but carries significant mortality risk 5
  • Adults over age 50 have a mortality rate of 1.8% compared to 0.3-0.6% overall 2

High-Risk Populations Requiring Enhanced Surveillance

Patients with underlying chronic liver disease (including hepatitis B or C coinfection) and immunocompromised individuals require careful monitoring. 2 These populations face higher risk of severe complications and should be followed more closely throughout the illness.

Post-Exposure Prophylaxis for Contacts

Administer post-exposure prophylaxis within 2 weeks of exposure for maximum effectiveness—efficacy drops significantly after this window. 2

Who Receives Prophylaxis

Provide prophylaxis to all household and sexual contacts of confirmed hepatitis A cases. 2

Choice of Prophylactic Agent

For healthy individuals aged ≥12 months, hepatitis A vaccine alone is now preferred over immune globulin. 2 The vaccine provides >85% protection when given before or within 2 weeks after exposure. 1

Use immune globulin specifically for: 2

  • Infants under 12 months of age
  • Immunocompromised persons
  • Patients with chronic liver disease
  • Those with contraindications to vaccination

Prevention in High-Risk Groups

Vaccinate all men who have sex with men, as this population experiences frequent outbreaks. 2 Additional vaccination targets include:

  • All persons who use injection or non-injection drugs 2
  • All patients with chronic liver disease, including those with hepatitis B and/or C coinfection 2
  • International travelers to endemic areas 1

Check hepatitis A total or IgG antibody 1-2 months after the second vaccine dose to confirm immunogenicity. 2

Critical Pitfalls to Avoid

Never delay post-exposure prophylaxis beyond 2 weeks, as efficacy drops precipitously after this timeframe. 2 This represents the single most important time-sensitive intervention.

Do not prescribe any medications metabolized by the liver during acute illness, as hepatic function is compromised. 2 This includes many commonly used drugs that could worsen liver injury.

Do not assume contacts are immune—verify immunity status and provide prophylaxis as indicated. 2 Even in vaccinated populations, breakthrough infections can occur, making contact tracing and prophylaxis essential.

Recognize that standard measures like condom use do not prevent hepatitis A transmission, as the fecal-oral route is the primary mode of spread. 1 Vaccination remains the only effective prevention strategy for at-risk populations.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis A Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Acute Viral Hepatitis.

Current treatment options in gastroenterology, 2000

Research

Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.